Marshall Wace’s ClearPoint Neuro CLPT Stock Holding History

Marshall Wace’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$476K	Buy	+52,259	New	+$660K	﹤0.01%	2475
2025 Q2	–	Sell	-87,634	Closed	-$1.04M	–	2758
2025 Q1	$1.04M	Buy	87,634 +74,781	+582%	+$1.16M	﹤0.01%	1762
2024 Q4	$198K	Sell	12,853 -263,779	-95%	-$3.42M	﹤0.01%	2357
2024 Q3	$3.1M	Buy	276,632 +218,372	+375%	+$2.09M	﹤0.01%	1198
2024 Q2	$314K	Buy	58,260 +38,984	+202%	+$226K	﹤0.01%	2131
2024 Q1	$131K	Buy	+19,276	New	+$135K	﹤0.01%	2281
2023 Q3	–	Sell	-26,372	Closed	-$191K	–	2251
2023 Q2	$191K	Buy	+26,372	New	+$224K	﹤0.01%	2247
2023 Q1	–	Sell	-18,046	Closed	-$153K	–	2716
2022 Q4	$153K	Buy	+18,046	New	+$171K	﹤0.01%	2736
2022 Q2	–	Sell	-32,033	Closed	-$333K	–	3472
2022 Q1	$333K	Sell	32,033 -26,532	-45%	-$241K	﹤0.01%	2936
2021 Q4	$657K	Buy	+58,565	New	+$877K	﹤0.01%	2670
2021 Q3	–	Sell	-56,391	Closed	-$1.08M	–	3062
2021 Q2	$1.08M	Buy	+56,391	New	+$1.09M	﹤0.01%	1771

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace's CLPT Position: Q1 2026 in Review

Marshall Wace opened a new position in ClearPoint Neuro (CLPT) in Q1 2026: 52,259 shares worth $476K. The stake represents ﹤0.01% of the portfolio and ranks #2475 among its holdings. This is a return to the name: Marshall Wace previously reported a position in CLPT as recently as Q1 2025.

Marshall Wace first reported a position in CLPT in Q2 2021 and has held it in 11 quarters since. The position peaked at $3.1M in Q3 2024. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

Marshall Wace held 52,259 shares of ClearPoint Neuro worth $476K as of Q1 2026.
ClearPoint Neuro was a new Marshall Wace position in Q1 2026.
ClearPoint Neuro made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2475 holding.
Marshall Wace first reported a position in ClearPoint Neuro in Q2 2021 and has held it in 11 quarters since.
Marshall Wace's ClearPoint Neuro position peaked at $3.1M in Q3 2024.
118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.